International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 8.6.2020
IMF to Host the 11th Annual International Myeloma Working Group (IMWG) Summit
This year’s gathering of the world’s top myeloma experts will convene online August 25-27 due to the pandemic. Despite the challenge of bringing together researchers from a myriad of time zones to a virtual setting, “It is extremely important to help keep myeloma research momentum going,” says IMF Chairman Dr. Brian G.M. Durie.
Register for the Next IMF Patient & Family Webinar
The next IMF Patient & Family Webinar is scheduled for Saturday, August 15, at 1:00 p.m. PT / 4:00 p.m. ET. This FREE two-hour webinar features a panel discussion about the latest treatments for and management of myeloma led by IMF Chairman Dr. Brian G.M. Durie. Panelists include Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen), Dr. Thomas Martin of the University of California San Francisco (UCSF) Health, and patient advocate Jack Aiello.
490x245 fda.png
FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Myeloma Patients
“On August 5, 2020, the Food and Drug Administration granted accelerated approval to belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.”
And This Too Shall Pass….
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself sipping a tropical beverage next to a private pool, just minutes from the Hawaiian coastline.
CDMRP Myeloma Research Programs Receive Funding
The IMF Advocacy Team lobbies yearly to gain inclusion of myeloma as an eligible disease to be funded by the Congressionally Directed Medical Research Program’s (CDMRP) Peer Reviewed Cancer Research Program (PRCRP). Due to the time it takes to determine which research to fund and to negotiate contracts for award money, the IMF Advocacy Team just received the full scope of research funded under PRCRP for fiscal year 2018 (FY18). With some excitement, the team shares how those funds will be used.
Learn About Initial Results of the KarMMa Trial
In this video, Dr. Nikhil Munshi (Dana-Farber Cancer Institute — Boston) breaks down the initial results from the KarMMa study. He explains that ide-cel, a B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy, demonstrated deep and durable responses in heavily pretreated relapsed/refractory multiple myeloma patients.
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

COVID-19 FAQ #19: Should myeloma patients visit the dentist during the pandemic?
Watch Now
Clinical Trials

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Miracles for Myeloma
Virtual 5K Run/Walk/Bike

Watch a Replay
Post-ASCO / Post-EHA Webinar

Hatfield Hike
Appalachian Trail

Click here to see all events

We Thank Our Sponsors:

Amgen; Bristol-Myers Squibb; Genentech; GSK; Oncopeptides, Inc.; Sanofi-Genzyme; and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page